ClinicalTrials.gg
Status unknownNCT03313661Updated Aug 27, 2018

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

A Phase 3 interventional study of Cabergoline and Gliclazide in Diabetes, sponsored by Sherief Abd-Elsalam. Status unknown at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2018-08-27.

Sponsored by Sherief Abd-Elsalam · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 146 studies in Diabetes Mellitus with a site in Egypt — 32 open to participants now, 41 under way, 2 of them phase 3. Diabetes Mellitus · Egypt.

Planned enrollment
46th of 101
60 · median 60
Started
2017
with 7 others
Phase 3
10 of 146
1 open now
Registered
27th of 146
by date

Among the 146 studies in Diabetes Mellitus with a site in Egypt, this one is the 46th largest by planned enrollment of the 101 interventional ones that give a count, is one of 8 that started in 2017, is one of 10 in phase 3, and was the 27th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

32 of the 146 studies in Diabetes Mellitus with a site in Egypt are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Diabetes Mellitus with a site in Egypt, or all of them as a file.
02

Study summary

Evaluation of the glycemic efficacy of cabergoline on diabetic patients

Read the detailed description

Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental part of the management of type 2 DM and difficult to achieve. Different antidiabetic agents can handle diabetic metabolic abnormalities. The development of antidiabetic agentswith novel mechanisms of action is highly desirable. Cabergoline, a long acting D2 agonist, is expected to play a role in the glycemic control.

03

Conditions studied

  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetic patients.

Exclusion criteria

Exclusion Criteria:

  • Other drugs administration
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cabergoline

    cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide

    Drug: Cabergoline

  • Active comparator
    Gliclazide

    gliclazide (60-120 mg) once daily

    Drug: Gliclazide

  • No intervention
    Placebo

    Placebo

Interventions

  • cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide

  • gliclazide (60-120 mg)

06

What researchers measure

Primary outcomes

  1. The level of fasting and post prandial BG level

    Fasting and post prandial BG level will be measured after 4 months

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
  • Sherief Abd-Elsalam
    Cairo, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2017 (actual). Primary completion is estimated for Oct 2020, 36 months after the start.

Of 63 non-industry phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 79. This study's planned 36 months is below that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2017
First posted
Oct 18, 2017
StartActual
Oct 14, 2017
Primary completionEst.
Oct 2020
CompletionEst.
Dec 2020
Last update
Aug 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03313661
Lead sponsor
Sherief Abd-Elsalam
Responsible party
Sherief Abd-Elsalam (PhDTropical Medicine, Tanta University) — Sponsor-investigator
First posted
Oct 18, 2017
Start date
Oct 14, 2017
Primary completion
Oct 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Aug 27, 2018

Study contacts

Sherief Abd-Elsalam, consultant
Contact
Sheriefabdelsalam@yahoo.com
00201095159522
Jouliana Atef Morcos, Msc
study chair · Faculty of Pharmacy, Tanta University, Egypt
Abla Mohamed Ebeid, Ph D
study chair · Faculty of Pharmacy, AL-Delta University, Gamasa, Egypt
Samy Abdel kader khodeir, Ph D
study chair · Faculty of Medicine, Tanta University
Gamal Abdel khalek Elazab, Ph D
study chair · Faculty of Pharmacy, Tanta University, Egypt

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabergoline

Start the discussion